<DOC>
	<DOCNO>NCT01582633</DOCNO>
	<brief_summary>This study evaluate immunological response safety profile seasonal , inactivated vaccine contain composition A/California/7/2009 H1N1 `` pandemic '' influenza virus , deliver via ID reduce dose ( 0,1 mL ) ( 0,2 mL ) , via IM full dose ( 0,5 mL ) deliver needle-free , disposable-syringe jet injector , control group via IM full dose ( 0,5 mL ) deliver syrinx needle subject 42 60 year old . Reduced dos skin deliver investigational intradermal model license , needle-free , disposable-syringe jet injector ( DSJI ) system , LECTRAJET速 M3 RA manufacture D'Antonio Consultants International , Inc. DSJIs avoid drawbacks danger conventional needle-syringe injection . Delivery DSJI skin also rapid simple overcomes difficulty patient discomfort traditional Mantoux needle method skin injection , use BCG vaccination tuberculosis skin test . Participants assess local systemic adverse event clinical observation immediately injection upon return day 21 injection . In addition , investigator call participant telephone day 2 7 day collect information local systemic side effect . Serum collect day 21 injection , assay hemagglutination inhibition ( HAI ) use conventional method perform Virology Lab Instituto de Medicina Tropical de S達o Paulo , blind study arm allocation participant . Information adverse event would collect day 1 , 3 7 dose delivery . The investigator assess adverse reaction blind study arm subject allocate . The primary endpoint study evaluate vaccine 's immunogenicity HAI , dose accordance international parameter include : seroconversion significant title increase ( SCR ) , frequency study arm seroprotection define post-vaccination titer &gt; 40 ( 1/dil ) ( SPR ) , well Geometric Mean Titers ( GMTRs ) post-vaccination serum .</brief_summary>
	<brief_title>Assessment Needle-free Disposable-syringe Jet Injector ( DSJI ) ID Dose-sparing Pandemic A H1N1 Influenza Vaccine</brief_title>
	<detailed_description>This study evaluate immunological response safety profile seasonal , inactivated vaccine contain composition A/California/7/2009 H1N1 `` pandemic '' influenza virus , deliver via ID reduce dose ( 0,1 mL ) ( 0,2 mL ) , via IM full dose ( 0,5 mL ) deliver needle-free , disposable-syringe jet injector , control group via IM full dose ( 0,5 mL ) deliver syrinx needle subject 42 60 year old . Reduced dos skin deliver investigational intradermal model license , needle-free , disposable-syringe jet injector ( DSJI ) system , LECTRAJET速 M3 RA manufacture D'Antonio Consultants International , Inc. ( East Syracuse , NY , USA ) . DSJIs avoid drawback danger conventional needle-syringe injection . Delivery DSJI skin also rapid simple overcomes difficulty patient discomfort traditional Mantoux needle method skin injection , use BCG vaccination tuberculosis skin test . Participants assess local systemic adverse event clinical observation immediately injection upon return day 21 injection . In addition , investigator call participant telephone day 2 7 day collect information local systemic side effect . Adverse event classify analyze accord case definition establish Brighton Collaboration Group . Serum collect day 21 injection , assay hemagglutination inhibition ( HAI ) use conventional method perform Virology Lab Instituto de Medicina Tropical de S達o Paulo , blind study arm allocation participant . Information adverse event would collect day 1 , 3 7 dose delivery . The investigator assess adverse reaction blind study arm subject allocate . The primary endpoint study evaluate vaccine 's immunogenicity HAI , dose accordance international parameter include : seroconversion significant title increase ( SCR ) , frequency study arm seroprotection define post-vaccination titer &gt; 40 ( 1/dil ) ( SPR ) , well Geometric Mean Titers ( GMTRs ) post-vaccination serum . Participants exclude prior history influenza disease cause A/California/7/2009 H1N1 prior vaccination , among exclusion inclusion criterion apply . Participants exclude retroactively analysis pre-vaccination HAI assay discovers pre-existing seroprotective titer &gt; 40 pandemic virus , represent preexist H1N1 exposure vaccination</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 42 60 year age . Available follow visit , least day 21 . Written inform consent sign volunteer reading explanation . Suspect verify diagnosis congenital acquire immunodeficiency include AIDS . Suspect verify diagnosis malignant neoplasia , basocellular carcinoma . Volunteer ongoing treatment high dos systemic corticosteroid ( equivalent prednisone ( 2 mg/kg/d two week ) immunosuppressant therapy . Received plan receive vaccine live attenuate strain virus within 30 day intend day ( ) study vaccination ( ) . Verified diagnosis Influenza A/California/H1N1 already immunize ( Influenza A/California/H1N1 ) . Suspect confirm pregnancy ( need pregnancy test , information possible pregnancy enough . These case must refer routine vaccination ) . Suspect verify diagnosis hypersensitivity ingredient vaccine , egg protein component vaccine lifethreatening reaction previous administration influenza vaccine . Any circumstance may potentially damage minor prevent procedure carry accord evaluation research team . Volunteer show sign symptom active intercurrent disease ( e.g . fever , rash , etc . ) may interfere evaluation adverse event follow immunization research team 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>vaccine</keyword>
	<keyword>influenza</keyword>
	<keyword>needle free jet injector</keyword>
	<keyword>Intradermal</keyword>
	<keyword>spar dose</keyword>
</DOC>